Reportlinker Adds Neuropathic Pain: Competing Treatments and Market Entry Considerations

Mar 29, 2011, 06:43 ET from Reportlinker

NEW YORK, March 29, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neuropathic Pain: Competing Treatments and Market Entry Considerations

http://www.reportlinker.com/p0287867/Neuropathic-Pain-Competing-Treatments-and-Market-Entry-Considerations.html

This report presents the findings of a global clinical survey on competing treatments for Neuropathic Pain (NP). These findings were made following the participation of more than 330 clinics, who provided details of their treatment practices. This survey was carried out to evaluate competing therapies and market entry factors, relating to the treatment of Neuropathic Pain.

With estimated prevalence levels of 3-10%, the treatment of Neuropathic Pain (NP) remains an area of significant unmet need. NP is highly individual in its presentation, level, underlying pathology and response to therapy. For some patients, available therapies give satisfactory pain control. For many others, treatments are poor or do not work at all. Therapeutic options include more than ten drug classes, which are commonly prescribed in combinations tailored to individual patient needs.

Overview:

• Comprehensive details of current treatments for NP, provided by more than 330 clinics in 56 countries

• In-depth information relevant to markets and opportunities in the NP field

• 98% of participants are practicing physicians, working in specialised areas of pain treatment. Of these, 78% described themselves as specialists in pain treatment

• Leading participant countries were USA, Canada, UK, Australia, Denmark, France, Brazil, Germany, Netherlands and Belgium

• 74% of the clinical centres participating in this study were hospital pain departments, specialised pain practices or private pain clinics. Detailed information on the use of specific drug classes including tricyclic antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers, opioids, NSAIDS, cannabinoids and Capsaicin

• Physicians have provided detailed feedback on the underlying pathologies associated with NP, seen in their patients

• Comprehensive information on the most frequently prescribed drugs from nine drugs classes, including drug combinations, for the treatment of NP. Biopharm Reports believes this provides the most comprehensive and up-to-date review and analysis in this area, currently available

• A detailed analysis of interventional methods used for the treatment of NP (e.g. peripheral nerve block, TENS)

• An assessment of average levels of pain relief achieved in the treatment of NP, in relation to 12 underlying conditions

• Informative views of participating physicians on current limitations, challenges and issues relating to the treatment of NP

Chapter Page

1. Introduction 12

2. Study Design and Conduct 15

3. Study Participants 21

4. Interventional Treatments 27

5. Underlying Diagnoses 31

6. Single or Multiple Drugs 41

7. Drug Classes 46

8. Tricyclic Antidepressants 53

9. Selective Serotonin Reuptake Inhibitors 56

10. Serotonin Noradrenalin Reuptake Inhibitors 60

11. Anticonvulsants 63

12. Sodium Channel Blockers 67

13. Opioids 70

14. Non Steroidal Anti Inflammatory Drugs 74

15. Drug Combinations 78

16. Pain Relief 91

17. Use of Interventional Treatments 101

18. Discussion 109

19. Participant Details 114

Appendix 1 118

Appendix 2 158

Report Figures and Tables

Figure 3.1 Participant Countries

Figure 3.2 Participant Organisations

Figure 3.3 Participating Physicians

Figure 4.1 The use of interventional treatments by participating physicians

Figure 5.1 Percentage of physicians indicating that 20% or more of their patients' Neuropathic Pain are

associated with the diagnosis indicated

Figure 5.2 Mean percentage of physicians (Mean%p) who diagnosed NP in patients with specific

underlying conditions

Figure 5.3 Neuropathic pain in patients associated with Diabetes

Figure 5.4 Neuropathic pain in patients associated with cancer radiotherapy or chemotherapy

Figure 5.5 Neuropathic pain in patients post general surgery

Figure 5.6 Neuropathic pain in patients with Trigeminal Neuralgia

Figure 5.7 Neuropathic pain in patients with viral infection

Figure 5.8 Neuropathic pain in patients with injury or trauma

Figure 5.9 Neuropathic pain in patients post back surgery

Figure 5.10 Neuropathic pain in patients with primary back problems

Figure 5.11 Neuropathic pain in patients with Complex Regional Pain Syndrome (CRPS)

Figure 5.12 Neuropathic pain in patients with Multiple Sclerosis

Figure 5.13 Neuropathic pain in patients with Central Pain

Figure 5.14 Neuropathic pain in patients with Arthritis

Figure 5.15 Neuropathic pain in patients with other conditions

Table 5.1 Other diagnoses associated with Neuropathic Pain

Table 6.1 Single drug use in the treatment of Neuropathic Pain

Table 6.2 Two drugs used in the treatment of Neuropathic Pain

Table 6.3 Three drugs used in the treatment of Neuropathic Pain

Table 6.4 More than three drugs used in the treatment of Neuropathic Pain

Table 6.5 Mean drug regimens in the treatment of Neuropathic Pain

Figure 7.1 Percentage of physicians prescribing the drug classes indicated, to more than 20% of their

patients

Figure 7.2 The use of Tricyclic antidepressants in the treatment of Neuropathic Pain

Figure 7.3 The use of Selective Serotonin Reuptake Inhibitors (SSRIs) in the treatment of Neuropathic

Pain

Figure 7.4 The use of Serotonin-Noradrenalin Reuptake Inhibitors (SNRIs) in the treatment of

Neuropathic Pain

Figure 7.5 The use of Anticonvulsants in the treatment of Neuropathic Pain

Figure 7.6 The use of Sodium Channel Blockers in the treatment of Neuropathic Pain

Figure 7.7 The use of Opioids in the treatment of Neuropathic Pain

Figure 7.8 The use of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in the treatment of Neuropathic

Pain

Figure 7.9 The use of Cannabinoids in the treatment of Neuropathic Pain

Figure 7.10 The use of Capsaicin in the treatment of Neuropathic Pain

Figure 7.11 Average drug class prescribing practices in the treatment of Neuropathic Pain

Figure 8.1 Most frequently prescribed tricyclic antidepressants in the treatment of Neuropathic Pain

Figure 8.2 Second most frequently prescribed tricyclic antidepressants in the treatment of Neuropathic

Pain

Figure 8.3 Third most frequently prescribed tricyclic antidepressants in the treatment of Neuropathic

Pain

Figure 9.1 Most frequently prescribed Selective Serotonin Reuptake Inhibitors (SSRIs) in the treatment

of Neuropathic Pain

Figure 9.2 Second most frequently prescribed Selective Serotonin Reuptake Inhibitors (SSRIs) in the

treatment of Neuropathic Pain

Figure 9.3 Third most frequently prescribed Selective Serotonin Reuptake Inhibitors (SSRIs) in the

treatment of Neuropathic Pain

Figure 10.1 Most frequently prescribed Serotonin-Noradrenalin Reuptake Inhibitors (SNRIs) in the

treatment of Neuropathic Pain

Figure 10.2 Second most frequently prescribed Serotonin-Noradrenalin Reuptake Inhibitors (SNRIs) in

the treatment of Neuropathic Pain

Figure 10.3 Third most frequently prescribed Serotonin-Noradrenalin Reuptake Inhibitors (SNRIs) in the

treatment of Neuropathic Pain

Figure 11.1 Most frequently prescribed Anticonvulsants in the treatment of Neuropathic Pain

Figure 11.2 Second most frequently prescribed Anticonvulsants in the treatment of Neuropathic Pain

Figure 11.3 Third most frequently prescribed Anticonvulsants in the treatment of Neuropathic Pain

Figure 12.1 Most frequently prescribed Sodium Channel Blockers in the treatment of Neuropathic Pain

Figure 12.2 Second most frequently prescribed Sodium Channel Blockers in the treatment of

Neuropathic Pain

Figure 12.3 Third most frequently prescribed Sodium Channel Blockers in the treatment of Neuropathic

Pain

Figure 13.1 Most frequently prescribed Opioids in the treatment of Neuropathic Pain

Figure 13.2 Second most frequently prescribed opioids in the treatment of Neuropathic Pain

Figure 13.3 Third most frequently prescribed opioids in the treatment of Neuropathic Pain

Figure 14.1 Most frequently prescribed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the

treatment of Neuropathic Pain

Figure 14.2 Second most frequently prescribed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the

treatment of Neuropathic Pain

Figure 14.3 Third most frequently prescribed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the

treatment of Neuropathic Pain

Table 15.1a Most frequently used drug class combinations for the treatment of Neuropathic Pain

Figure 15.1 Most frequently used drug class combinations for the treatment of Neuropathic Pain

Figure 15.2 Most frequently used numbers of drugs used in the treatment of Neuropathic Pain.

Table 15.2a Second most frequently used drug class combinations for the treatment of Neuropathic

Pain.

Figure 15.3 Second most frequently used drug class combinations for the treatment of Neuropathic

Pain.

Figure 15.4 Second most frequently used drug numbers used in the treatment of Neuropathic Pain.

Table 15.3a. Third most frequently used drug class combinations for the treatment of Neuropathic Pain.

Figure 15.5 Third most frequently used drug class combinations for the treatment of Neuropathic Pain.

Figure 15.6 Third most frequently used numbers of drugs in the treatment of Neuropathic Pain

Figure 16.1 Average relief from Neuropathic Pain (% reduction) following treatment in patients with

Diabetes.

Figure 16.2 Average relief from Neuropathic Pain (% reduction) following treatment in patients with

cancer radiotherapy or cancer chemotherapy

Figure 16.3 Average relief from Neuropathic Pain (% reduction) following treatment in patients following

general surgery

Figure 16.4 Average relief from Neuropathic Pain (% reduction) following treatment in patients with

Trigeminal Neuralgia

Figure 16.5 Average relief from Neuropathic Pain (% reduction) following treatment in patients with viral

infection.

Figure 16.6 Average relief from Neuropathic Pain (% reduction) following treatment in patients with

injury or trauma

Figure 16.7 Average relief from Neuropathic Pain (% reduction) following treatment in patients post back

surgery.

Figure 16.8 Average relief from Neuropathic Pain (% reduction) following treatment in patients with

primary back problems

Figure 16.9 Average relief from Neuropathic Pain (% reduction) following treatment in patients with

Complex Regional Pain Syndrome (CRPS)

Figure 16.10 Average relief from Neuropathic Pain (% reduction) following treatment in patients with

Multiple Sclerosis

Figure 16.11 Average relief from Neuropathic Pain (% reduction) following treatment in patients with

Central Pain.

Figure 16.12 Average relief from Neuropathic Pain (% reduction) following treatment in patients with

Arthritis.

Figure 16.13 Average relief from Neuropathic Pain (% reduction) following treatment in patients with

other conditions.

Figure 16.14 Comparative average relief from NP (% reduction) following pain treatment in for all

underlying conditions

Table 16.1 Comparative average relief from NP (% reduction) following pain treatment in for all

underlying conditions

Figure 17.1 The percentage of physicians who use interventional treatments for Neuropathic Pain

Figure 17.2 The use of interventional treatments by physicians for Neuropathic Pain (number of

practitioner responses for each treatment)

Figure 17.3 The use of interventional treatments by physicians for Neuropathic Pain (average % of

physicians using treatments)

Table 17.1 The use of interventional treatments by physicians for Neuropathic Pain (number of

practitioner responses for each treatment)

Table 17.2 The use of interventional treatments by physicians for Neuropathic Pain (average % of

physicians using treatments)

Table 17.3 Other interventional treatments used by physicians for the treatment of Neuropathic Pain

Figure 19.1 Study participants

Appendix 1. Responses of study participants to the question: What are the major issues and challenges

associated with the treatment of neuropathic pain? Responses given by physicians to this question

(which in some cases may be brief, informal or abbreviated) are presented "as is", except in those cases

where minor grammatical or typographical corrections have been necessary for reasons of clarity.

Appendix 2. Responses of study participants to the question: Any further comments relating to the

treatment of Neuropathic Pain? Responses physicians to this question by physicians (which in some

cases may be brief, informal or abbreviated) are presented "as is", except in those cases where minor

grammatical or typographical corrections have been necessary for reasons of clarity.

To order this report:

: Neuropathic Pain: Competing Treatments and Market Entry Considerations

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com